South Korea–based Nature Cell has officially selected Baltimore City as the home of a new 100,000-square-foot stem-cell manufacturing and R&D facility. The announcement adds new momentum to Maryland’s growing profile as a global destination for advanced therapeutics manufacturing.
The facility, located at 1401 Severn Street in the Gaslight Square complex, will be developed by Nature Cell America in two phases, with work projected through 2031. Company officials estimate that the site will support roughly 500 full-time jobs once fully operational.
Maryland officials framed the move as further validation of the state’s competitive advantage in cell and gene therapy manufacturing, research, and workforce readiness. Baltimore has a rich history in stem cell manufacturing dating back to 2012 when Osiris Therapeutics received the first regulatory clearance in the world for a systemically administered stem cell drug called Prochymal.
Governor Wes Moore said in a statement that “Maryland continues to lead in life sciences innovation and Nature Cell’s investment reinforces our reputation as a global hub for biotechnology and advanced research.”
Baltimore Mayor Brandon M. Scott highlighted the significance of redeveloping the Severn Street site, noting that “Nature Cell’s decision to bring cutting-edge innovation to one of our city’s historic industrial sites shows what’s possible when we connect our legacy of manufacturing strength with our growing life sciences sector.”
The company expects the Baltimore operation to play a central role in the development and production of “JointStem,” its investigational stem-cell therapy for knee osteoarthritis, while also expanding research into Alzheimer’s disease. According to the announcement, the new facility is expected to support the production of up to one million doses annually.
In explaining the company’s selection of Maryland, Nature Cell Chairman Dr. Jeong-Chan Ra cited both the state’s regulatory and funding environment—such as the Maryland Stem Cell Research Fund—and the region’s depth of technical talent. “We have chosen Maryland for the site … after a comprehensive evaluation of the state’s exceptional ecosystem for our business,” he said. “Maryland offers an abundant pool of highly skilled technical talent that is critical to establishing global leadership and setting industry standards in stem cell therapeutics.”
A Broader Pattern of International Investment
Nature Cell’s announcement follows a series of international life-science companies choosing Maryland for U.S. expansion. Earlier this year, India-based Syngene International selected Baltimore for its first North American biomanufacturing facility, a project expected to create approximately 300 jobs and further diversify the region’s biotech manufacturing landscape.
Adding to this global pipeline, TEDCO recently signed a joint declaration with Korea Venture Investment Corporation to strengthen international collaboration, innovation exchange, and technology commercialization between Maryland and South Korea. The agreement reinforces the cross-border ties driving many of the recent investment decisions seen across the region.
The convergence of new manufacturing investment, global partnerships, and specialized workforce programs continues to elevate Maryland—particularly the Baltimore–Washington corridor—as a nationally competitive hub for cell therapy, gene therapy, and advanced biologics production. For the Greater Baltimore area, Nature Cell’s new facility represents both an economic milestone and a signal that international therapeutics developers increasingly view the region as a strategic foothold for U.S. growth.
